A blood cancer drug created by Melbourne researchers over 30 years has been approved for use in Australia, giving hope to ...

Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...

Around 100,000 Australians live with myelofibrosis, which is a rare form of blood cancer. But an Australian-developed drug - ...

Geron Corporation's RYTELO gains FDA approval for Low-Risk MDS, with strong sales projections and promising Phase 3 study.

Around 100,000 Australians live with a rare form of blood cancer, and a new treatment approved by the medicines watchdog is ...

Patients with myelofibrosis who cleared their mutations 30 days following stem cell transplantation experienced fewer relapses. They also achieved longer DFS and OS. Patients with myelofibrosis ...

FIU softball coach Mike Larabee stepped down temporarily Saturday, after being diagnosed with a form of blood cancer, and he ...

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

There is a simple discount patient access scheme for fedratinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

In LR-MDS, abnormal bone marrow cells often express the enzyme ... from any other drug currently approved or in development for myelofibrosis treatment; (ii) that the early results from IMproveMF ...

"There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” said Simrit Parmar, MD, Founder of Cellenkos.